Back to top

Morgan Stanley Sticks to Its Buy Rating for Ascendis Pharma (ASND)

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Ascendis Pharma, with a price target of $275.00. According ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ascendis Pharma A/S (ASND)